AUROPHARMA — Aurobindo Pharma Share News
0.000.00%
Last trade - 00:00- IN₹904.32bn
- IN₹877.78bn
- IN₹336.53bn
HSBC sees no earnings hit from FDA action on India's Aurobindo Pharma
India's Aurobindo Pharma down after US FDA flags serious concerns at facility
Brief: Aurobindo Pharma Says FDA Classifies Eugia Unit-III Inspection As Official Action Indicated
Brief: Aurobindo Pharma Receives Final US FDA Approval For Tofacitinib Tablets, 5 Mg And 10 Mg
India Stocks: Indian shares on track for lower open as US-Iran tensions unsettle markets
Brief: Aurobindo Pharma Says Unit Incorporates New Subsidiary, Arrow Pharma Production SAS, In France
India's Aurobindo Pharma falls after Q4 results; Ambit flags project delays, weak free cash flow
Brief: Aurobindo Pharma Posts March-Qtr Consol Net PAT 9.21 Billion Rupees
Brief: Aurobindo Pharma Says US FDA Inspects Unit-VII In Telangana
Brief: Aurobindo Pharma Says Unit Secures Health Canada NOC For Bevqolva Bevacizumab Biosimilar
Brief: Aurobindo Pharma Receives USFDA Approval For Dextromethorphan Polistirex Extended-Release Oral Suspension
Brief: Aurobindo Pharma Receives USFDA Approval For Glycerol Phenylbutyrate Oral Liquid, 1.1 Grams Per Ml
Brief: Aurobindo Pharma Says Theranym Biologics Announces Additional Product Schedule With MSD
Brief: Aurobindo Pharma Receives USFDA Approval For Dapagliflozin And Metformin Hydrochloride Extended-Release Tablets
Brief: Aurobindo Pharma Says Co Receives USFDA Approval For Dapagliflozin Tablets, 5 Mg And 10 Mg
Brief: Aurobindo Pharma Says Curateq Biologics Announces Positive Phase 3 Results For Omalizumab Biosimilar Bp11
Brief: Aurobindo Pharma To Consider Buyback Of Equity Shares
Brief: Aurobindo Pharma Says Co's Subsidiary Curateq Biologics Enters Marketing And Distribution Agreement With STADA Arzneimittel AG
UBS initiates Indian pharma coverage amid weight-loss drug opportunity